Exact Sciences Corporation (NASDAQ:EXAS) Q3 2023 Earnings Conference Call November 1, 2023 5:00 PM ET

Company Participants

Kevin Conroy - Chairman, Chief Executive Officer

Jeff Elliott - Chief Financial Officer

Everett Cunningham - Chief Commercial Officer

Erik Holznecht - Manager, Investor Relations

Conference Call Participants

Catherine Schulte - Baird

Brandon Couillard - Jefferies

Derik de Bruin - Bank of America

Dan Brennan - TD Cowen

Andrew Brackmann - William Blair

Vijay Kumar - Evercore ISI

Matt Sykes - Goldman Sachs

Patrick Donnelly - Citi

Jack Meehan - Nephron Research

Puneet Souda - Leerink

Dan Arias - Stifel

Dan Leonard - UBS

Mark Massaro - BTIG

Kyle Mikson - Canaccord

Eve Burstein - Burstein

Albert Hu - Craig-Hallum

Operator

Good afternoon, ladies and gentlemen, and welcome to the Exact Sciences Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode, and please be advised that this call is being recorded. After the speakers prepared remarks, there will be a question-and-answer session. [Operator Instructions].

And now at this time, I would like to turn the call over to Mr. Erik Holznecht, Manager of Investor Relations. Please go ahead, sir.

Erik Holznecht

Thanks, Beau. Thank you for joining us for Exact Sciences third quarter 2023 conference call. On the call today are Kevin Conroy, the company's Chairman and CEO, and Jeff Elliott, our Chief Financial Officer. Everett Cunningham, our Chief Commercial Officer, will also be available for questions.

Exact Sciences issued a news release earlier this afternoon detailing our third quarter financial results. This news release and today's presentation are available on our website at exactsciences.com.

During today's call, we will make forward-looking statements based on current expectations. Our actual results may be materially different from such statements. Discussions of non-GAAP figures and reconciliations to GAAP figures are available in our earnings press release, and descriptions of the risks and uncertainties associated with Exact Sciences are included in our SEC filings. Both can be accessed through our website.

I'll now turn the call over to Kevin.

Kevin Conroy

Thank you, Erik. Our third quarter results reflect our commitment to help eradicate cancer with tests that prevent it, detect it earlier, and guide its treatment. Cologuard and Oncotype DX fuel are growing $2.5 billion business and the next wave of breakthrough cancer diagnostic innovations. Our focus on solving the needs of patients and healthcare providers powered outstanding third quarter results, allowing us to raise our 2023 guidance, for both revenue and adjusted EBITDA.